Monovalent Influenza Vaccine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza, Healthy
Trial Timeline
May 2, 2016 → Nov 30, 2016
NCT ID
NCT02743117About Monovalent Influenza Vaccine
Monovalent Influenza Vaccine is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02743117. Target conditions include Influenza, Healthy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03158038 | Approved | Completed |
| NCT02743117 | Approved | Completed |
Competing Products
20 competing products in Influenza